(firstQuint)Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B.

 Phase IV, open-label, non comparative, multicenter, previously treated patients (PTP) clinical trial.

 Patients with severe or moderate hemophilia B with baseline levels of plasma factor IX < 5% activity will participate in this study for both treatment regimens: "on demand" therapy for acute bleeding episodes and therapy for prophylaxis of bleeding episodes ( "Short-term therapy")*.

 * Short-Term Therapy: Prophylactic therapy given before surgery, including dental procedures, prior to a event that would likely result in bleeding ( sports, exercise, or heavy work), as well as to prevent further bleeds into a target joint).

 This short-term therapy for intermittent secondary therapy.

.

 Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B@highlight

To assess efficacy and safety of BeneFix(R) for prophylaxis in "Short-term" therapy and on demand therapy for all bleeding episodes of subjects with hemophilia B.

